» Articles » PMID: 2413997

Definition by Monoclonal Antibodies of a Repertoire of Epitopes on Carcinoembryonic Antigen Differentially Expressed in Human Colon Carcinomas Versus Normal Adult Tissues

Overview
Journal Cancer Res
Specialty Oncology
Date 1985 Nov 1
PMID 2413997
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Monoclonal antibodies (MAbs) designated COL-1 through 15 have been generated and characterized and show a strong degree of selective reactivity for human colon carcinomas versus normal adult tissues. To prepare the MAbs, mice were immunized with extracts or membrane-enriched fractions of biopsy material from either primary or metastatic colon carcinoma lesions. The fifteen COL MAbs, all of the immunoglobulin G subclasses 1, 2a, or 2b, reacted with purified carcinoembryonic antigen in solid-phase radioimmunoassay and by immunoblotting, but none reacted with human polymorphonuclear leukocytes or certain spleen preparations previously shown to be rich in carcinoembryonic antigen-related or cross-reactive antigens. MAbs COL-1 through 15 could be divided into at least five groups based on their differential range of reactivities to the surface of colon carcinoma cells or other carcinoma cell preparations. The COL MAbs were tested via immunoperoxidase with a wide range of primary and metastatic colon carcinomas, benign or dysplastic colon lesions, and 34 normal adult tissues. With few exceptions, the COL MAbs tested in this manner showed reactivity only to the primary and metastatic colon carcinomas. These studies thus provide a well-characterized repertoire of MAbs that are well suited for potential clinical trials involving the radiolocalization and possibly therapy of human colon carcinoma lesions. The fact that at least five epitopes are being recognized also provides the opportunity for testing the efficacy of cocktails of the COL MAbs toward these goals.

Citing Articles

MIRD Pamphlet No. 31: MIRDcell V4-Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy.

Katugampola S, Wang J, Howell R J Nucl Med. 2024; 65(12):1965-1973.

PMID: 39448267 PMC: 11619582. DOI: 10.2967/jnumed.123.267238.


Longitudinal Evaluation of AFP and CEA External Proficiency Testing Reveals Need for Method Harmonization.

Wojtalewicz N, Vierbaum L, Kaufmann A, Schellenberg I, Holdenrieder S Diagnostics (Basel). 2023; 13(12).

PMID: 37370914 PMC: 10296933. DOI: 10.3390/diagnostics13122019.


A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.

Gatti-Mays M, Strauss J, Donahue R, Palena C, Del Rivero J, Redman J Clin Cancer Res. 2019; 25(16):4933-4944.

PMID: 31110074 PMC: 6697621. DOI: 10.1158/1078-0432.CCR-19-0183.


A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Duggan M, Jochems C, Donahue R, Richards J, Karpa V, Foust E Cancer Immunol Immunother. 2016; 65(11):1353-1364.

PMID: 27581603 PMC: 5071149. DOI: 10.1007/s00262-016-1893-7.


A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.

Donahue R, Duncan B, Fry T, Jones B, Bachovchin W, Kiritsy C Vaccine. 2014; 32(26):3223-31.

PMID: 24731809 PMC: 4059051. DOI: 10.1016/j.vaccine.2014.04.008.